Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | UBE2M | P61081 | 2/20 | 0.41 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5829862 | 0.91 | OPRD1 (0.58) | OPRD1OPRM1OPRK1PARP1CYP3A4 | |
| SCHEMBL5879373 | 0.91 | OPRD1 (0.70) | OPRD1OPRM1OPRK1 | |
| SCHEMBL5830263 | 0.90 | OPRD1 (0.68) | OPRD1OPRM1OPRK1CHRM3 | |
| SCHEMBL5830256 | 0.89 | OPRD1 (0.50) | OPRD1OPRM1OPRK1PARP1PARP2 | |
| SCHEMBL5829658 | 0.87 | OPRD1 (0.51) | OPRD1OPRM1OPRK1CHRM3CYP3A4 | |
| SCHEMBL5829870 | 0.85 | OPRM1 (0.53) | OPRD1OPRM1OPRK1PARP1 | |
| SCHEMBL5830028 | 0.85 | OPRD1 (0.55) | OPRD1OPRM1OPRK1PARP2 | |
| SCHEMBL6751100 | 0.85 | OPRD1 (0.55) | OPRD1OPRM1OPRK1PARP1PARP2 | |
| SCHEMBL6600742 | 0.84 | OPRD1 (0.49) | OPRD1OPRM1OPRK1CYP3A4 | |
| SCHEMBL5829833 | 0.83 | OPRD1 (0.60) | OPRD1OPRM1OPRK1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142966-A1 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2004-07-22 | — | — | US | claimed |
| EP-1395557-A1 | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | AstraZeneca AB (SE) | 2004-03-10 | — | — | EP | claimed |
| WO-2002094785-A1 | 4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2002-11-28 | — | — | WO | claimed |
| US-7008952-B2 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142966-A1 | 4-(phenyl-(piperidin-4yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders | HTR2C, HTR1D, HTR1A | OPRD1 5/4885OPRM1 17/4885OPRK1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.